论文部分内容阅读
[目的]探讨联合检测细胞角蛋白19(CK19)mRNA和CK19蛋白在恶性胸腔积液患者诊断中的价值。[方法]32例恶性胸腔积液患者和30例良性胸腔积液患者的胸水标本,以定量逆转录—聚合酶链反应法(RT-PCR)测定胸液CK19mRNA和酶联免疫吸附法(ELISA)测定胸液CK19蛋白。[结果]恶性良性胸腔积液组CK19mRNA的阳性率分别为62.5%和16.7%;恶性良性胸液组CK19蛋白的阳性率为43.8%和10.0%(P<0.01)。联合检测胸液CK19mRNA和CK19蛋白诊断恶性胸腔积液敏感性和准确性分别为81.3%和79.0%。[结论]CK19mRNA和CK19蛋白联合检测可提高恶性胸腔积液诊断的准确性,对良恶性胸腔积液的鉴别诊断有重要参考价值。
[Objective] To investigate the value of combined detection of cytokeratin 19 (CK19) mRNA and CK19 protein in the diagnosis of patients with malignant pleural effusion. [Methods] Pleural effusion specimens from 32 patients with malignant pleural effusion and 30 patients with benign pleural effusion were assayed by quantitative reverse transcription-polymerase chain reaction (RT-PCR) for CK19 mRNA in pleural effusion and enzyme linked immunosorbent assay (ELISA) Determination of CK19 protein in pleural fluid. [Results] The positive rates of CK19 mRNA in malignant benign pleural effusion group were 62.5% and 16.7% respectively. The positive rates of CK19 protein in malignant benign pleural effusion group were 43.8% and 10.0%, respectively (P <0.01). The sensitivity and accuracy of the combined detection of pleural CK19mRNA and CK19 protein in the diagnosis of malignant pleural effusion were 81.3% and 79.0%, respectively. [Conclusions] The combined detection of CK19 mRNA and CK19 protein can improve the accuracy of diagnosis of malignant pleural effusion, which has important reference value in the differential diagnosis of benign and malignant pleural effusions.